221 related articles for article (PubMed ID: 32712535)
1. Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors.
Jia H; Yu J; Du X; Cherukupalli S; Zhan P; Liu X
Eur J Med Chem; 2020 Sep; 202():112495. PubMed ID: 32712535
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors.
Jia H; Bai F; Liu N; Liang X; Zhan P; Ma C; Jiang X; Liu X
Eur J Med Chem; 2016 Nov; 123():202-210. PubMed ID: 27484509
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors.
Ma Y; Zhao S; Ren Y; Cherukupalli S; Li Q; Woodson ME; Bradley DP; Tavis JE; Liu X; Zhan P
Eur J Med Chem; 2021 Dec; 225():113780. PubMed ID: 34438123
[TBL] [Abstract][Full Text] [Related]
4. Identification of (6S)-cyclopropyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxamines as new HBV capsid assembly modulators.
Lv K; Wu S; Tao Z; Wang A; Xu S; Yang L; Gao Q; Wang A; Qin X; Jiang B; Wu W; Jia X; Li Y; Jiang J; Liu M
Eur J Med Chem; 2022 Jan; 228():113974. PubMed ID: 34772528
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors.
Jia H; Song Y; Yu J; Zhan P; Rai D; Liang X; Ma C; Liu X
Eur J Med Chem; 2017 Aug; 136():144-153. PubMed ID: 28494252
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of novel heteroaryldihydropyrimidine derivatives as non-nucleoside hepatitis B virus inhibitors by exploring the solvent-exposed region.
Yu J; Jia H; Guo X; Desta S; Zhang S; Zhang J; Ding X; Liang X; Liu X; Zhan P
Chem Biol Drug Des; 2020 Jun; 95(6):567-583. PubMed ID: 30825248
[TBL] [Abstract][Full Text] [Related]
7. A new series of HAPs as anti-HBV agents targeting at capsid assembly.
Yang XY; Xu XQ; Guan H; Wang LL; Wu Q; Zhao GM; Li S
Bioorg Med Chem Lett; 2014 Sep; 24(17):4247-9. PubMed ID: 25127104
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel dihydrobenzodioxine derivatives as HBV capsid protein inhibitors.
Liu L; Wang M; Li C; Han X; Xie Y; Feng K; Zhang L; Chen Y; Jia H
Bioorg Chem; 2022 Nov; 128():106052. PubMed ID: 35921789
[TBL] [Abstract][Full Text] [Related]
9. Identification of a new class of HBV capsid assembly modulator.
Kuduk SD; Stoops B; Alexander R; Lam AM; Espiritu C; Vogel R; Lau V; Klumpp K; Flores OA; Hartman GD
Bioorg Med Chem Lett; 2021 May; 39():127848. PubMed ID: 33610748
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.
Liu S; Wei W; Li Y; Liu X; Cao X; Lei K; Zhou M
Eur J Med Chem; 2015 May; 95():473-82. PubMed ID: 25847765
[TBL] [Abstract][Full Text] [Related]
11. Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.
Zhao J; Tu J; Fan N; Chen X; Lu F; Zhang Y; Zhang L; Tian C; Zhang Z; Liu J; Wang X
Future Med Chem; 2016 May; 8(7):751-63. PubMed ID: 27172826
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors.
Qiu J; Gong Q; Gao J; Chen W; Zhang Y; Gu X; Tang D
Eur J Med Chem; 2018 Jan; 144():424-434. PubMed ID: 29288943
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of aminothiazole based Hepatitis B Virus (HBV) capsid inhibitors.
Pan T; Ding Y; Wu L; Liang L; He X; Li Q; Bai C; Zhang H
Eur J Med Chem; 2019 Mar; 166():480-501. PubMed ID: 30739828
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.
Boucle S; Lu X; Bassit L; Ozturk T; Russell OO; Amblard F; Coats SJ; Schinazi RF
Bioorg Med Chem Lett; 2017 Feb; 27(4):904-910. PubMed ID: 28094179
[TBL] [Abstract][Full Text] [Related]
15. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
Ren Q; Liu X; Luo Z; Li J; Wang C; Goldmann S; Zhang J; Zhang Y
Bioorg Med Chem; 2017 Feb; 25(3):1042-1056. PubMed ID: 28082068
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays.
Wang Y; Wang Z; Liu J; Wang Y; Wu R; Sheng R; Hou T
Bioorg Med Chem; 2021 Apr; 36():116096. PubMed ID: 33721800
[TBL] [Abstract][Full Text] [Related]
17. Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly.
Toyama M; Sakakibara N; Takeda M; Okamoto M; Watashi K; Wakita T; Sugiyama M; Mizokami M; Ikeda M; Baba M
Virus Res; 2019 Oct; 271():197677. PubMed ID: 31376401
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, molecular docking studies and anti-HBV activity of phenylpropanoid derivatives.
Liu S; Li Y; Wei W; Wang K; Wang L; Wang J
Chem Biol Interact; 2016 May; 251():1-9. PubMed ID: 26980103
[TBL] [Abstract][Full Text] [Related]
19. 2-Arylthio-5-iodo pyrimidine derivatives as non-nucleoside HBV polymerase inhibitors.
Wang J; Zhang L; Zhao J; Zhang Y; Liu Q; Tian C; Zhang Z; Liu J; Wang X
Bioorg Med Chem; 2018 May; 26(8):1573-1578. PubMed ID: 29459146
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
Wang LJ; Geng CA; Ma YB; Huang XY; Luo J; Chen H; Guo RH; Zhang XM; Chen JJ
Bioorg Med Chem; 2012 May; 20(9):2877-88. PubMed ID: 22472044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
